Oncol-话题@MedSci

#Oncol#

2384篇内容 | 2461人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1866360, encodeId=efd6186636067, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：血糖控制对晚期非小细胞肺癌(NSCLC)伴有糖尿病患者的生存影响, objectType=article, longId=220720, objectId=1b0a220e20cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b0a220e20cb, replyNumber=0, likeNumber=52, createdTime=2022-05-01, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b0a220e20cb, moduleTitle=Front Oncol：血糖控制对晚期非小细胞肺癌(NSCLC)伴有糖尿病患者的生存影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b0a220e20cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866561, encodeId=e3571866561c0, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：超重时间越久，结直肠癌风险越高！, objectType=article, longId=301366, objectId=ed5e301366c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed5e301366c5, replyNumber=0, likeNumber=72, createdTime=2022-11-28, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed5e301366c5, moduleTitle=JAMA Oncol：超重时间越久，结直肠癌风险越高！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ed5e301366c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866366, encodeId=3864186636648, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：回顾性分析伊立替康治疗既往接受过蒽环类和紫杉类药物的转移性乳腺癌患者的疗效, objectType=article, longId=220842, objectId=ae42220842c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae42220842c2, replyNumber=0, likeNumber=0, createdTime=2022-05-20, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae42220842c2, moduleTitle=Front Oncol：回顾性分析伊立替康治疗既往接受过蒽环类和紫杉类药物的转移性乳腺癌患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae42220842c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866072, encodeId=29c518660e236, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Oncologist：西米普利单抗+放疗+环磷酰胺+GM-CSF治疗复发/转移性头颈部鳞状细胞癌的疗效和安全性, objectType=article, longId=210895, objectId=1c9e21089525, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c9e21089525, replyNumber=0, likeNumber=67, createdTime=2022-02-22, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c9e21089525, moduleTitle=Oncologist：西米普利单抗+放疗+环磷酰胺+GM-CSF治疗复发/转移性头颈部鳞状细胞癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c9e21089525)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866122, encodeId=8c1e18661222d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究, objectType=article, longId=213120, objectId=686b21312019, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=686b21312019, replyNumber=0, likeNumber=76, createdTime=2022-04-02, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=686b21312019, moduleTitle=J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=686b21312019)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866112, encodeId=4bd718661120e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, objectType=article, longId=212750, objectId=8752212e509b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8752212e509b, replyNumber=0, likeNumber=82, createdTime=2021-09-06, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8752212e509b, moduleTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8752212e509b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866057, encodeId=390f186605ef8, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：晚期卵巢癌患者不宜采用免疫检查点抑制剂治疗！, objectType=article, longId=210475, objectId=0be72104e5b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0be72104e5b3, replyNumber=0, likeNumber=69, createdTime=2021-11-04, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0be72104e5b3, moduleTitle=J Clin Oncol：晚期卵巢癌患者不宜采用免疫检查点抑制剂治疗！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0be72104e5b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866080, encodeId=c0221866080d1, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, objectType=article, longId=211283, objectId=6e722112837b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6e722112837b, replyNumber=0, likeNumber=77, createdTime=2021-12-26, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e722112837b, moduleTitle=Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e722112837b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866475, encodeId=813318664e538, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncology：背靠背！吴一龙/周彩存团队发现舒格利单抗可治疗转移性/不可切除性非小细胞肺癌, objectType=article, longId=294982, objectId=f5d12949827b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5d12949827b, replyNumber=0, likeNumber=75, createdTime=2022-10-19, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5d12949827b, moduleTitle=Lancet Oncology：背靠背！吴一龙/周彩存团队发现舒格利单抗可治疗转移性/不可切除性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5d12949827b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866486, encodeId=eb95186648697, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：Pyrotinib联合卡培他滨治疗HER2阳性乳腺癌患者脑转移的疗效, objectType=article, longId=295056, objectId=30a9295056e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30a9295056e6, replyNumber=0, likeNumber=69, createdTime=2022-08-20, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30a9295056e6, moduleTitle=Lancet Oncol：Pyrotinib联合卡培他滨治疗HER2阳性乳腺癌患者脑转移的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30a9295056e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866511, encodeId=f8c818665110d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=期刊推荐：JCO Oncology Practice, objectType=article, longId=295750, objectId=660b295e50f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=660b295e50f6, replyNumber=0, likeNumber=19, createdTime=2022-10-03, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=660b295e50f6, moduleTitle=期刊推荐：JCO Oncology Practice, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=660b295e50f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866210, encodeId=55e2186621016, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：溶瘤柯萨奇病毒A21(V937)治疗不可切除的黑色素瘤的临床反应和安全性, objectType=article, longId=216578, objectId=b7f12165e835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7f12165e835, replyNumber=0, likeNumber=79, createdTime=2022-05-28, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7f12165e835, moduleTitle=J Clin Oncol：溶瘤柯萨奇病毒A21(V937)治疗不可切除的黑色素瘤的临床反应和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7f12165e835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866114, encodeId=efde1866114c4, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, objectType=article, longId=212816, objectId=bee72128164e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bee72128164e, replyNumber=0, likeNumber=63, createdTime=2022-01-05, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bee72128164e, moduleTitle=Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bee72128164e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866253, encodeId=65ff1866253d5, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=JAMA Oncol：Ivosidenib (AG-120)可改善经治IDH1突变肝内胆管细胞癌患者的总生存：III期ClarIDHy研究最终OS分析结果, objectType=article, longId=217781, objectId=606a21e7812d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=606a21e7812d, replyNumber=0, likeNumber=63, createdTime=2022-01-05, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=606a21e7812d, moduleTitle=JAMA Oncol：Ivosidenib (AG-120)可改善经治IDH1突变肝内胆管细胞癌患者的总生存：III期ClarIDHy研究最终OS分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=606a21e7812d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866062, encodeId=974e186606284, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Lancet Oncol：癌症患者能接种新冠疫苗吗？接种效果如何？, objectType=article, longId=210594, objectId=0eaa2105942c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0eaa2105942c, replyNumber=0, likeNumber=70, createdTime=2021-08-30, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0eaa2105942c, moduleTitle=Lancet Oncol：癌症患者能接种新冠疫苗吗？接种效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0eaa2105942c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866231, encodeId=a93c186623143, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：氟尿嘧啶/亚叶酸联合帕尼单抗维持治疗可显著延长RAS野生型转移性结直肠癌患者的生存期, objectType=article, longId=217301, objectId=986821e3019a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=986821e3019a, replyNumber=0, likeNumber=147, createdTime=2022-04-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=986821e3019a, moduleTitle=J Clin Oncol：氟尿嘧啶/亚叶酸联合帕尼单抗维持治疗可显著延长RAS野生型转移性结直肠癌患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=986821e3019a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866227, encodeId=30bf186622ea6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：新确诊的多发性骨髓瘤患者的巩固和维持治疗, objectType=article, longId=217223, objectId=cc2f21e223a1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc2f21e223a1, replyNumber=0, likeNumber=94, createdTime=2021-10-01, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc2f21e223a1, moduleTitle=J Clin Oncol：新确诊的多发性骨髓瘤患者的巩固和维持治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc2f21e223a1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866169, encodeId=79bf18661695e, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Ann Oncol：派姆单抗在局部晚期/复发性/转移性皮肤鳞状细胞癌中的疗效实锤！, objectType=article, longId=214810, objectId=c1e621481097, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1e621481097, replyNumber=0, likeNumber=65, createdTime=2021-12-29, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1e621481097, moduleTitle=Ann Oncol：派姆单抗在局部晚期/复发性/转移性皮肤鳞状细胞癌中的疗效实锤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1e621481097)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866553, encodeId=a51a18665537d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=J Clin Oncol：奥拉帕利±西地尼布 vs 化疗治疗复发性铂敏感性卵巢癌, objectType=article, longId=301138, objectId=85c9301138b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=85c9301138b8, replyNumber=0, likeNumber=80, createdTime=2022-11-16, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=85c9301138b8, moduleTitle=J Clin Oncol：奥拉帕利±西地尼布 vs 化疗治疗复发性铂敏感性卵巢癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=85c9301138b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1866344, encodeId=712a18663446d, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, objectTitle=Front Oncol：晚期胆管癌一线和二线治疗疗效，以及剂量下调时对疗效影响 , objectType=article, longId=220211, objectId=7218220211e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7218220211e4, replyNumber=0, likeNumber=76, createdTime=2022-09-13, rootId=0, userName=minlingfeng, userId=b63894, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7218220211e4, moduleTitle=Front Oncol：晚期胆管癌一线和二线治疗疗效，以及剂量下调时对疗效影响 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7218220211e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Oncol

2020-05-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：血糖控制对晚期非小细胞肺癌(NSCLC)伴有糖尿病患者的生存影响

2022-05-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：超重时间越久，结直肠癌风险越高！

2022-11-28

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：回顾性分析伊立替康治疗既往接受过蒽环类和紫杉类药物的转移性乳腺癌患者的疗效

2022-05-20

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Oncologist：西米普利单抗+放疗+环磷酰胺+GM-CSF治疗复发/转移性头颈部鳞状细胞癌的疗效和安全性

2022-02-22

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Thorac Oncol: 替雷利珠单抗（Tislelizumab）联合化疗一线治疗局部进展或转移性非鳞状非小细胞肺癌（nsq-NSCLC）的疗效和安全性(RATIONALE 304): 3期临床研究

2022-04-02

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189

2021-09-06

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：晚期卵巢癌患者不宜采用免疫检查点抑制剂治疗！

2021-11-04

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet oncol：Loncastuximab tesirine可有效治疗复发性/难治性DLBCL！

2021-12-26

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncology：背靠背！吴一龙/周彩存团队发现舒格利单抗可治疗转移性/不可切除性非小细胞肺癌

2022-10-19

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：Pyrotinib联合卡培他滨治疗HER2阳性乳腺癌患者脑转移的疗效

2022-08-20

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

期刊推荐：JCO Oncology Practice

2022-10-03

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：溶瘤柯萨奇病毒A21(V937)治疗不可切除的黑色素瘤的临床反应和安全性

2022-05-28

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet oncol：单用avelumab或联合PLD可显著延长铂类耐药/难治性卵巢癌的生存预后

2022-01-05

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

JAMA Oncol：Ivosidenib (AG-120)可改善经治IDH1突变肝内胆管细胞癌患者的总生存：III期ClarIDHy研究最终OS分析结果

2022-01-05

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Lancet Oncol：癌症患者能接种新冠疫苗吗？接种效果如何？

2021-08-30

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：氟尿嘧啶/亚叶酸联合帕尼单抗维持治疗可显著延长RAS野生型转移性结直肠癌患者的生存期

2022-04-16

爆笑小医 (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：新确诊的多发性骨髓瘤患者的巩固和维持治疗

2021-10-01

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Ann Oncol：派姆单抗在局部晚期/复发性/转移性皮肤鳞状细胞癌中的疗效实锤！

2021-12-29

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

J Clin Oncol：奥拉帕利±西地尼布 vs 化疗治疗复发性铂敏感性卵巢癌

2022-11-16

minlingfeng (审核中...)

前往app查看评论内容

#Oncol#

Front Oncol：晚期胆管癌一线和二线治疗疗效，以及剂量下调时对疗效影响

2022-09-13

科室
- - 订阅+
  - 更多科室
工具
服务